The genetic understanding of SMN2 as a modifier of SMA, combined with the biochemical understanding that more copies of SMN2 results in increased full-length SMN protein, indicated a strong target for therapeutics to increase full-length SMN protein. Here, SMN1 is linked to proximal spinal muscular atrophy.